Cardiorenal syndromes (CRS) have been recently classified into five distinct entities, each with different major pathophysiologic mechanisms. CRS type 1 most commonly occurs in the setting of acutely decompensated heart failure where approximately 25% of patients develop a rise in serum creatinine and a reduction of urine output after the first several doses of intravenous diuretics. Altered cardiac and renal hemodynamics are believed to be the most important determinants of CRS type 1. CRS type 2 is the hastened progression of chronic kidney disease (CKD) in the setting of chronic heart failure. Accelerated renal cell apoptosis and replacement fibrosis is considered to be the dominant mechanism. CRS type 3 is acutely decompensated heart failure after acute kidney injury from inflammatory, toxic, or ischemic insults. This syndrome is precipitated by salt and water overload, acute uremic myocyte dysfunction, and neurohormonal dysregulation. CRS type 4 is manifested by the acceleration of the progression of chronic heart failure in the setting of CKD. Cardiac myocyte dysfunction and fibrosis, so-called ‘CKD cardiomyopathy', is believed to be the predominant pathophysiologic mechanism. Type 5 CRS is simultaneous acute cardiac and renal injury in the setting of an overwhelming systemic insult such as sepsis. In this scenario, the predominant pathophysiological disturbance is microcirculatory dysfunction as a result of acutely abnormal immune cell signaling, catecholamine cellular toxicity, and enzymatic activation which result in simultaneous organ injury often extending beyond both the heart and the kidneys. This paper will summarize these and other key findings from an international consensus conference on the spectrum of pathophysiologic mechanisms at work in the CRS.

1.
Ledoux P: Cardiorenal syndrome (in French). Avenir Med 1951;48:149-153.
[PubMed]
2.
Blair JE, Manuchehry A, Chana A, Rossi J, Schrier RW, Burnett JC, Gheorghiade M: Prognostic markers in heart failure - congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care 2007;9:207-213.
[PubMed]
3.
Sarraf M, Masoumi A, Schrier RW: Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009;4:2013-2026.
[PubMed]
4.
Sarraf M, Schrier RW: Cardiorenal syndrome in acute heart failure syndromes. Int J Nephrol 2011;2011:293938.
[PubMed]
5.
Brammah A, Robertson S, Tait G, Isles C: Bilateral renovascular disease causing cardiorenal failure. BMJ 2003;326:489-491.
[PubMed]
6.
Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B: The severe cardiorenal syndrome: ‘Guyton revisited'. Eur Heart J 2005;26:11-17.
[PubMed]
7.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
[PubMed]
8.
Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Acute Dialysis Quality Initiative (ADQI) Consensus Group: Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. Basel, Karger, 2010, vol 165, pp 54-67.
[PubMed]
9.
Kellum JA, Bellomo R, Ronco C: Acute Dialysis Quality Initiative (ADQI): methodology. Int J Artif Organs 2008;31:90-93.
[PubMed]
10.
Bongartz LG, Braam B, Gaillard CA, Cramer MJ, Goldschmeding R, Verhaar MC, Doevendans PA, Joles JA: Target organ crosstalk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012;303:F1253-F1263.
[PubMed]
11.
Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-67.
[PubMed]
12.
Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-141.
[PubMed]
13.
Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW: Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-1804.
[PubMed]
14.
Haase M, Mueller C, Damman K, Murray P: Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure: Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI), 2013.
[PubMed]
15.
Ross EA: Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail 2012;18:930-938.
[PubMed]
16.
Tarantini L, Cioffi G, Gonzini L, Oliva F, Lucci D, Di Tano G, Maggioni AP, Tavazzi L, Italian Acute Heart Failure Survey: Evolution of renal function during and after an episode of cardiac decompensation: results from the Italian survey on acute heart failure. J Cardiovasc Med (Hagerstown) 2010;11:234-243.
[PubMed]
17.
Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr: Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197-2205.
[PubMed]
18.
Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand IS, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD: Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011;4:613-620.
[PubMed]
19.
Jao GT, Chiong JR: Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options. Clin Cardiol 2010;33:666-671.
[PubMed]
20.
Maisel AS, Katz N, Hillege HL, Shaw A, Zanco P, Bellomo R, Anand I, Anker SD, Aspromonte N, Bagshaw SM, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, House AA, Mankad S, McCullough P, Mebazaa A, Palazzuoli A, Ponikowski P, Ronco F, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ronco C, Acute Dialysis Quality Initiative Consensus Group: Biomarkers in kidney and heart disease. Nephrol Dial Transplant 2011;26:62-74.
[PubMed]
21.
Aldous SJ, Richards AM, Troughton R, Than M: ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 2012;18:304-310.
[PubMed]
22.
Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL: Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008;14:732-738.
[PubMed]
23.
Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP: High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-187.
[PubMed]
24.
Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL: Interleukin-33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011;161:1163-1170.
[PubMed]
25.
Vallon V, Miracle C, Thomson S: Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 2008;10:176-187.
[PubMed]
26.
Tojo A, Gross SS, Zhang L, Tisher CC, Schmidt HH, Wilcox CS, Madsen KM: Immunocytochemical localization of distinct isoforms of nitric oxide synthase in the juxtaglomerular apparatus of normal rat kidney. J Am Soc Nephrol 1994;4:1438-1447.
[PubMed]
27.
Singh P, Okusa MD: The role of tubuloglomerular feedback in the pathogenesis of acute kidney injury. Contrib Nephrol. Basel, Karger, 2011, vol 174, pp 12-21.
[PubMed]
28.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
[PubMed]
29.
Matsushima H, Machiguchi T, Muso E, Matusyama E, Tamura T, Sasayama S: Urinary albumin and TGF-1 levels as renal damage indices in patients with congestive heart failure. Clin Exp Nephrol 2002;6:9.
30.
Salmon AH, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, Bates DO, Peti-Peterdi J: Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012;23:1339-1350.
[PubMed]
31.
Valente MA, Damman K, Dunselman PH, Hillege HL, Voors AA: Urinary proteins in heart failure. Prog Cardiovasc Dis 2012;55:44-55.
[PubMed]
32.
Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 2006;69:440-449.
[PubMed]
33.
Shrestha K, Shao Z, Singh D, Dupont M, Tang WH: Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol 2012;110:1329-1335.
[PubMed]
34.
McCullough PA, Olobatoke A, Vanhecke TE: Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12:200-210.
[PubMed]
35.
Dang Z, MacKinnon A, Marson LP, Sethi T: Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012;93:477-484.
[PubMed]
36.
Dorai T, Fishman AI, Ding C, Batinic-Haberle I, Goldfarb DS, Grasso M: Amelioration of renal ischemia-reperfusion injury with a novel protective cocktail. J Urol 2011;186:2448-2454.
[PubMed]
37.
Cruz DN, Schmidt-Ott KM, Vescovo G, House AA: Cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the 11th ADQI Consensus Conference, 2013.
[PubMed]
38.
Cruz DN, Gheorghiade M, Palazzuoli A, Ronco C, Bagshaw SM: Epidemiology and outcome of the cardiorenal syndrome. Heart Fail Rev 2011;16:531-542.
[PubMed]
39.
Bagshaw SM, Hoste E, Braam B, Brigouri C: Cardiorenal syndrome type III: pathophysiologic and epidemiologic considerations, 2013.
[PubMed]
40.
Feltes CM, Van Eyk J, Rabb H: Distant-organ changes after acute kidney injury. Nephron Physiol 2008;109:p80-p84.
[PubMed]
41.
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-244.
[PubMed]
42.
Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV: Urinary kidney injury molecule-1:a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290:F517-F529.
[PubMed]
43.
Carlsson AC, Larsson A, Helmersson-Karlqvist J, Lind L, Ingelsson E, Larsson TE, Sundström J, Arnlöv J: Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. Eur J Heart Fail 2012 (E-pub ahead of print).
[PubMed]
44.
Chuasuwan A, Kellum JA: Cardiorenal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012;32:31-39.
[PubMed]
45.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047.
[PubMed]
46.
Larsen T, Narala KR, McCullough PA: Type 4 cardiorenal syndrome: myocardial dysfunction, fibrosis, and heart failure in patients with chronic kidney disease. J Clin Exp Cardiol 2012;3:4.
47.
Marinescu V, McCullough PA: Managing comorbidities; in Bakris G, Baliga RR (eds): Chronic Kidney Disease, chapt 5D: Hypertension. New York, Oxford American Cardiology Library/Oxford University Press, 2012, pp 71-81.
48.
Hanson ID, McCullough PA: B-type natriuretic peptide: beyond diagnostic applications; in Bakris GL (ed): The Kidney in Heart Failure. New York, Springer, 2012;67-77.
49.
Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, Gupta S, Tian J, Morgan E, Khouri S, Cooper CJ, Periyasamy SM, Xie Z, Malhotra D, Fedorova OV, Bagrov AY, Shapiro JI: Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 2008;294:F450-F454.
[PubMed]
50.
Peng YS, Ding HC, Lin YT, Syu JP, Chen Y, Wang SM: Uremic toxin p-cresol induces disassembly of gap junctions of cardiomyocytes. Toxicology 2012;302:11-17.
[PubMed]
51.
McMahon AC, Naqvi RU, Hurst MJ, Raine AE, MacLeod KT: Diastolic dysfunction and abnormality of the Na+/Ca2+ exchanger in single uremic cardiac myocytes. Kidney Int 2006;69:846-851.
[PubMed]
52.
Tumlin JA, Costanzo MR, Chawla LS, Herzog CA: Cardiorenal Syndrome Stage IV: Clinical Presentation and Pathophysiology, 2013.
[PubMed]
53.
Faul C: Fibroblast growth factor-23 and the heart. Curr Opin Nephrol Hypertens 2012;21:369-375.
[PubMed]
54.
Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG: FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012;27:727-733.
[PubMed]
55.
Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, Deloach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-586.
[PubMed]
56.
McCullough PA, Nowak RM, Foreback C, Tokarski G, Tomlanovich MC, Khoury N, Weaver WD, Sandberg KR, McCord J: Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002;162:2464-2468.
[PubMed]
57.
Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011;6:1326-1332.
[PubMed]
58.
Han YL, Li YL, Jia LX, Cheng JZ, Qi YF, Zhang HJ, Du J: Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang-II-induced cardiac inflammation and fibrosis. PLoS One 2012;7:e35506.
[PubMed]
59.
Soni SS, Ronco C, Pophale R, Bhansali AS, Nagarik AP, Barnela SR, Saboo SS, Raman A: Cardiorenal syndrome type 5: epidemiology, pathophysiology, and treatment. Semin Nephrol 2012;32:49-56.
[PubMed]
60.
Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-121.
[PubMed]
61.
Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA: Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003;14:1022-1030.
[PubMed]
62.
Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, Dhainaut JF, Mira JP, Chiche JD: Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32:660-665.
[PubMed]
63.
Ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000;46:650-657.
[PubMed]
64.
Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR: Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004;95:13-17.
[PubMed]
65.
Chelazzi C, Villa G, De Gaudio AR: Cardiorenal syndromes and sepsis. Int J Nephrol 2011;2011:652967.
[PubMed]
66.
Mohaupt M, Kramer HJ: Acute ischemic renal failure: review of experimental studies on pathophysiology and potential protective interventions. Ren Fail 1989-1990;11:177-185.
[PubMed]
67.
Vriz O, Minisini R, Citro R, Guerra V, Zito C, De Luca G, Pavan D, Pirisi M, Limongelli G, Bossone E: Analysis of β1- and β2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy. Acta Cardiol 2011;66:787-790.
[PubMed]
68.
Celes MR, Prado CM, Rossi MA: Sepsis: going to the heart of the matter. Pathobiology 2013;80:70-86.
[PubMed]
69.
Mehta RL, Rabb H, Shaw A, Singbartl K: Cardiorenal Syndrome Type 5: Clinical Presentation, Pathophysiology and Management Strategies. Summary of Recommendations from the Acute Dialysis Quality Initiative Consensus Conference, 2013.
[PubMed]
70.
Rudiger A, Dyson A, Felsmann K, Carré JE, Taylor V, Hughes S, Clatworthy I, Protti A, Pellerin D, Lemm J, Claus RA, Bauer M, Singer M: Early functional and transcriptomic changes in the myocardium predict outcome in a long-term rat model of sepsis. Clin Sci (Lond) 2013;124:391-401.
[PubMed]
71.
Gao M, Ha T, Zhang X, Liu L, Wang X, Kelley J, Singh K, Kao R, Gao X, Williams D, Li C: Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 2012;40:2390-2399.
[PubMed]
72.
Ferreira AM, Sakr Y: Organ dysfunction: general approach, epidemiology, and organ failure scores. Semin Respir Crit Care Med 2011;32:543-551.
[PubMed]
73.
Chelazzi C, Villa G, De Gaudio AR: Cardiorenal syndromes and sepsis. Int J Nephrol 2011;2011:652967.
[PubMed]
You do not currently have access to this content.